Insulin biosimilars Market Key Players, Growth Rate And Forecast To 2033

The new report published by The Business Research Company, titled Insulin biosimilars Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the insulin biosimilars market size has grown rapidly in recent years. It will grow from $2.64 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $5.41 billion in 2028 at a compound annual growth rate (CAGR) of 15.2%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=10661&type=smp

Surge In Diabetes Drives The Market Growth Of Insulin Biosimilars
The increasing prevalence of diabetes is expected to propel the growth of the insulin biosimilars market going forward. Diabetes refers to a group of chronic metabolic disorders characterized by high blood sugar levels over a prolonged period. Biosimilars play a crucial role in the treatment of diabetes by providing an alternative option for insulin therapy, as a result, the increasing prevalence of diabetes increases the demand for insulin biosimilars market. For instance, in December 2021, according to the International Diabetes Federation (IDFT), a Belgium-based federal agency, the number of people with diabetes would increase to 643 million by 2030 and 783 million by 2045. Additionally, over 1.2 million children and adolescents (aged 0-19 years) are currently living with type 1 diabetes. Therefore, increasing the prevalence of diabetes drives the insulin biosimilar market.

Industry Players Drive Innovation In The Insulin Biosimilar Landscape
Product innovation has emerged as a key trend gaining popularity in the insulin biosimilar market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in July 2021, Biocon Biologics, an India-based company manufacturing insulin biosimilars in collaboration with Viatris Inc., a US-based pharmaceutical company, received approval for the first Interchangeable Biosimilar Semglee (insulin glargine-yfgn injection) for the treatment of diabetes from The U.S. Food and Drug Administration (FDA), a US-based government agency. This product is a significant breakthrough in the treatment of diabetes, as it is indicated for adults and pediatric patients aged 6 years and older with both type 1 and type 2 diabetes and is a crucial milestone that holds the potential for cost savings and improved access to affordable treatment options for individuals suffering from diabetes.

The insulin biosimilars market covered in this report is segmented -

1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars
2) By Disease Indication Type: Type I Diabetes, Type II Diabetes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @

https://www.thebusinessresearchcompany.com/Discount?id=10661&type=discount

Major companies operating in the insulin biosimilars market report are Eli Lilly and Company,Boehringer Ingelheim GmbH,Merck & Co Inc.,Pfizer Inc.,Biocon Ltd.,Mylan N.V.,Wockhardt Limited,NOVO Nordisk A/S,Sanofi S.A,Ypsomed AG,Fresenius Kabi AG,Sandoz International GmbH,Novartis International AG,Aurobindo Pharma Ltd.,Intas Pharmaceuticals Ltd.,Dr. Reddy's Laboratories Ltd.,Amgen Inc., Samsungbioepis Co. Ltd.,Coherus BioSciences Inc .,Teva Pharmaceutical Industries Ltd.,Stada Arzneimittel AG,Celltrion Inc.,Biogen Inc., AstraZeneca plc,Fujifilm Kyowa Kirin Biologics Co. Ltd.,Mochida Pharmaceutical Co. Ltd.,Daiichi Sankyo Company Limited,LG Chem Ltd.,JCR Pharmaceuticals Co. Ltd.,Green Cross Corporation,Lupin Limited,Torrent Pharmaceuticals Ltd.,Zydus lifescience Ltd.

Contents of the report:
1. Executive Summary
2. Insulin biosimilars Market Report Structure
3. Insulin biosimilars Market Trends And Strategies
4. Insulin biosimilars Market - Macro Economic Scenario
5. Insulin biosimilars Market Size And Growth
…..
27. Insulin biosimilars Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.